{
    "id": "dbpedia_8095_0",
    "rank": 71,
    "data": {
        "url": "https://finance.yahoo.com/news/global-active-pharmaceutical-ingredients-api-120800626.html",
        "read_more_link": "",
        "language": "en",
        "title": "Global Active Pharmaceutical Ingredients (API) and Pharmaceutical Excipients Market Research Report 2022-2029 - Increasing Scope of HPAPI and Advanced Next Generation Biologics Market",
        "top_image": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
        "meta_img": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
        "images": [
            "https://finance.yahoo.com/_td_api/beacon/info?beaconType=noJSenabled&bucket=finance-US-en-US-def&code=pageRender&device=desktop&lang=en-US&pageName=deeplink&region=US&rid=598for1jc408j&site=finance&t=1723990291639",
            "https://s.yimg.com/ny/api/res/1.2/el.HV.i1tSb18Rn3x4cz7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1MjtoPTQ4/https://s.yimg.com/os/creatr-uploaded-images/2022-01/ff845300-7fab-11ec-beff-9bd353ee8bcc",
            "https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65",
            "https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65",
            "https://s.yimg.com/ny/api/res/1.2/yL11hrJ_z9.QQRfSEyF0kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MA--/https://ml.globenewswire.com/media/NjcxZWJiZmItMDNlYi00ZDhlLTk3YmYtYzE0YjU5M2NlMGI3LTEwMjY3Mzc=/tiny/Research-and-Markets.png",
            "https://s.yimg.com/ny/api/res/1.2/yL11hrJ_z9.QQRfSEyF0kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MA--/https://ml.globenewswire.com/media/NjcxZWJiZmItMDNlYi00ZDhlLTk3YmYtYzE0YjU5M2NlMGI3LTEwMjY3Mzc=/tiny/Research-and-Markets.png",
            "https://sb.scorecardresearch.com/p?c1=2&c2=7241469&c5=1183300001&c7=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fglobal-active-pharmaceutical-ingredients-api-120800626.html&c14=-1"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Research and Markets"
        ],
        "publish_date": "2023-03-06T12:08:00+00:00",
        "summary": "",
        "meta_description": "Dublin, March 06, 2023 (GLOBE NEWSWIRE) -- The \"Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2029\" & \"Pharmaceutical Excipients Global Market - Forecast To 2029\" report has been added to ResearchAndMarkets.com's offering. Generally, each drug made up of two components that are API and excipients, having curative activity. APIs are often known as bulk pharmaceuticals and most of all APIs are in powder form. Active Pharmaceutical Ingredients (APIs) are active substances in a",
        "meta_lang": "en",
        "meta_favicon": "https://s.yimg.com/rz/l/favicon.ico",
        "meta_site_name": "Yahoo Finance",
        "canonical_link": "https://finance.yahoo.com/news/global-active-pharmaceutical-ingredients-api-120800626.html",
        "text": "Dublin, March 06, 2023 (GLOBE NEWSWIRE) -- The \"Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2029\" & \"Pharmaceutical Excipients Global Market - Forecast To 2029\" report has been added to ResearchAndMarkets.com's offering.\n\nGenerally, each drug made up of two components that are API and excipients, having curative activity. APIs are often known as bulk pharmaceuticals and most of all APIs are in powder form. Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized based on chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source.\n\nNorth America accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Growing pharma R&D expenditure, increasing development of new drugs over the time, increasing approval of generics and biosimilars, growing biopharmaceutical drugs pipelines, presence of number of API manufacturing facilities for all regulated drug products, increasing scope of highly potent drugs, government support to expand the domestic pharmaceutical manufacturing facilities and increase in the prevalence of infectious diseases, cancer, central nervous system associated diseases, cardiac disease, and musculoskeletal disorder are some of the major diseases that are driving the market growth. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2022 to 2029.\n\nThe factors such as increasing generic pharmaceuticals and vaccines production, number of pharma companies with a strong network of manufacturing facilities, increasing outsourcing with number of CMO's and expanding manufacturing facilities, increasing development of new pharma and biopharma drugs, growing biotech R&D investment, presence of number of innovative biotech startups, presence of dedicated departments to support biotechnology research, increasing government investment to support the pharma and biotech industry, low labor cost, and increased prevalence of infectious and other chronic diseases are driving the market growth.\n\nSome of the key players of Active pharmaceutical Ingredient (API) market are\n\nCatalent Inc.\n\nDivis Laboratories\n\nEuroapi\n\nLonza Group Ltd.\n\nPfizer Inc.\n\nSamsung Biologics Co. Ltd.\n\nTeva Pharmaceutical Industries Limited.\n\nThermo Fisher Scientific Inc\n\nWuxi Apptec Co. Ltd.\n\nWuxi Biologics (Cayman) Inc.\n\nKey Topics Covered:\n\n1 Executive Summary\n\n2 Introduction\n\n2.1 Key Takeaways\n\n2.2 Scope of the Report\n\n2.3 Report Description\n\n2.4 Markets Covered\n\n2.5 Stakeholders\n\n2.6 Research Methodology\n\n3 Market Analysis\n\n3.1 Introduction\n\n3.2 Market Segmentation\n\n3.3 Factors Influencing Market\n\n3.3.1 Drivers and Opportunities\n\n3.3.1.1 Increasing Incidence and Prevalence of Chronic, Communicable and Autoimmune Diseases\n\n3.3.1.2 Adoption of Biologics in Disease Management and Increasing Regulatory Approvals\n\n3.3.1.3 Increasing Investment in Research and Development (R&D) and Expansion of Manufacturing Facilities\n\n3.3.1.4 Patent Expiration of Major Drugs\n\n3.3.1.5 Increasing Scope of Hpapi and Advanced Next Generation Biologics Market\n\n3.3.1.6 Increasing Trend of Outsourcing and Adoption in Emerging Market\n\n3.3.1.7 Increase in the Geriatric Population\n\n3.3.2 Restraints and Threats\n\n3.3.2.1 Contamination of API\n\n3.3.2.2 High Cost for Manufacturing Apis\n\n3.3.2.3 a Requirement of Highly Skilled Technicians\n\n3.3.2.4 Pierce Competition Between API Players\n\n3.3.2.5 Presence of Alternatives\n\n3.3.2.6 Stringent Regulatory Policies and Environmental Concerns\n\n3.4 Regulatory Affairs\n\n3.5 Technological Advancements\n\n3.5.1 Introduction\n\n3.5.2 Automation and Control\n\n3.5.3 Continuous Flow Manufacturing\n\n3.5.4 Cryogenic Technology\n\n3.5.5 Single - Use System (Sus)\n\n3.5.6 Artificial Intelligence in API Manufacturing\n\n3.5.7 Chemistry in Water\n\n3.5.8 M-Rna Technology in Vaccine Manufacturing\n\n3.5.9 Advancements in Hpapi Manufacturing\n\n3.6 Porter's Five Force Analysis\n\n3.7 Supply Chain Analysis\n\n3.8 Market Share Analysis\n\n3.9 Fda Approved API Manufacturing Units\n\n3.10 Pharmaceutical API Production Volume\n\n3.11 Patent Expiry and Anda Approvals\n\n3.12 Drug Master Filing (Dmf)\n\n3.13 Repurposed Drugs for COVID-19 Treatment\n\n3.14 Acquisition, Merger, and Expansions in API Manufacturing\n\n3.15 Selected Top Selling API\n\n3.16 API Manufacturers Revenue and Capabilities Table\n\n4 API Global Market, Based on Synthesis\n\n4.1 Introduction\n\n4.2 Synthetic API\n\n4.2.1 Synthetic API Based on Customer Base\n\n4.3 Biotech API\n\n4.3.1 Antibodies\n\n4.3.2 Recombinant Proteins\n\n4.3.3 Vaccines\n\n4.3.4 Gene Therapy\n\n4.3.5 Cell Therapy\n\n4.3.6 Other Biotech API\n\n4.3.7 Biotech API Based on Customer Base\n\n4.3.7.1 Biologic API\n\n4.3.7.2 Biosimilar API\n\n4.4 Hpapi\n\n4.4.1 Hpapi Based on Customer Base\n\n5 API Global Market, Based on Business Type\n\n5.1 Introduction\n\n5.2 Captive API Based on Type\n\n5.2.1 Branded Captive API\n\n5.2.2 Generic Captive API\n\n5.3 Merchant API Based on Type\n\n5.3.1 Branded Merchant API\n\n5.3.2 Generic Merchant API\n\n6 API Global Market, Based on Application\n\n6.1 Introduction\n\n6.2 Infectious Diseases\n\n6.3 Oncology\n\n6.4 Cardiovascular Diseases\n\n6.5 Central Nervous System\n\n6.6 Pulmonary Diseases\n\n6.7 Gastrointestinal Diseases\n\n6.8 Endocrine Diseases\n\n6.9 Metabolic Disorders\n\n6.10 Genitourinary Diseases\n\n6.11 Musculoskeletal Diseases\n\n6.12 Other Applications (Nephrology, Hepatology, Opthalmology, Dental, Pain Management, Dermatology,Ent Etc.,)\n\n7 Regional Analysis\n\n7.1 Introduction\n\n7.2 North America\n\n7.2.1 U.S.\n\n7.2.2 Rest of North America\n\n7.3 Europe\n\n7.3.1 Italy\n\n7.3.2 Germany\n\n7.3.3 France\n\n7.3.4 Rest of Europe\n\n7.4 APAC\n\n7.4.1 China\n\n7.4.2 Japan\n\n7.4.3 India\n\n7.4.4 Rest of APAC\n\n7.5 RoW\n\n7.5.1 Brazil\n\n7.5.2 Rest of Latam\n\n7.5.3 Middle East & Others\n\n8 Competitive Landscape\n\n8.1 Introduction\n\n8.2 Collaboration, Partnership and Agreement\n\n8.3 Expansion\n\n8.4 Approvals\n\n8.5 New Product, Service and Technology Launch\n\n8.6 Acquisition\n\n8.7 Others\n\n9 Major Companies\n\n9.1 Overview\n\n9.2 Financials\n\n9.3 Service Portfolio\n\n9.4 Key Developments\n\n9.5 Business Strategy\n\n9.6 SWOT Analysis\n\nCompanies Mentioned\n\nAarti Drugs Ltd\n\nAbbVie Inc.\n\nACIC Pharmaceuticals Inc.\n\nAdimmune Corporation\n\nAjinomoto Bio-Pharma Services\n\nAlbemarle Corporation\n\nAlembic Ltd\n\nAlkem laboratories Ltd.\n\nAlmac Group\n\nAlven Laboratories S.r.o.\n\nAmbio Pharma Inc.\n\nAmneal Pharmaceuticals Inc.\n\nApicore LLC\n\nAragen Life Sciences (GVK Biosciences Private Limited)\n\nArene Lifesciences Limited.\n\nAstraZeneca plc\n\nAurobindo Pharma\n\nAmpac fine chemicals LLC\n\nAxplora\n\nBASF SE\n\nBayer AG\n\nBachem holding AG\n\nBal Pharma Ltd.\n\nBiocon Limited\n\nBiogen Inc.\n\nBiomarin Pharmaceutical Inc\n\nBiophore India Pharmaceuticals Pvt. Ltd.\n\nBiosortia Pharmaceuticals Inc.\n\nBiotechnica Pharma Global\n\nBlanver\n\nBoehringer Ingelheim GmbH\n\nBrawn Biotech Ltd.\n\nBristol-Myers Squibb Company\n\nCadila Pharmaceuticals Limited\n\nCuria\n\nCatalent, Inc.\n\nCayman Chemicals\n\nCelltrion Inc.,\n\nCambrex Corporation\n\nCentury Pharmaceuticals Ltd\n\nCFM Group (AMSA S.P.A)\n\nChangzhou Pharmaceutical Factory\n\nChemCon GmbH\n\nChina Chemical & Pharmaceutical Co., Ltd.\n\nChongqing Huapont Pharmaceutical CO LTD,\n\nCipla Limited\n\nCKD Bio\n\nCorden Pharma International (Germany)\n\nCSL Ltd\n\nDaiichi Sankyo Chemical Pharma Co Ltd\n\nDaito Pharmaceutical Co., Ltd\n\nDishman Carbogen Amcis\n\nDr.Reddy's Laboratories\n\nEisai Co., Ltd.\n\nEli Lilly and Company\n\nEmcure Pharmaceuticals Ltd.\n\nErcros S.A.\n\nEstechpharma Co., Ltd.\n\nEsteve Quimica SA\n\nEverest Organics Limited\n\nEvonik Industries AG\n\nF. Hoffmann-La Roche AG\n\nFareva Group\n\nFIS Fabbrica Italiana Sintetici SPA\n\nFlamma S.p.A\n\nFormosa Laboratories, Inc.\n\nFuji Chemical Industry Co.,Ltd\n\nGentec Pharmaceutical Group S.A (DUKE CHEM and PHARMANOID)\n\nGilead Sciences, Inc.\n\nGivaudan (Indena)\n\nGland Pharma Limited\n\nGlaxoSmithKline plc\n\nGlenmark Pharmaceutical Ltd.\n\nGRANULES INDIA LTD.\n\nGrupo Ferrer Internacional S.A (Interquim, S.A)\n\nHarman Finochem Limited.\n\nHeraeus Holding GmbH\n\nHetero Labs Ltd.\n\nHikma pharmaceuticals\n\nHybio Pharmaceutical Co., Ltd.\n\nHikal Ltd.\n\nIbio Inc\n\nInabata Co. Ltd.\n\nINTAS PHARMACEUTICALS LTD,\n\nJeil Pharmaceutical Co. Ltd.,\n\nJohnson and Johnson\n\nJohnson Matthey Pharma Services Inc.\n\nJubilant lifesciences (Jubilant generics Ltd)\n\nKatsura Chemical Co.,Ltd.\n\nKern Pharma, S.L.,\n\nKleos pharma\n\nKocak Farma Pharmaceutical\n\nKosher Pharmaceuticals\n\nKrka, tovarna zdravil, d. d., Novo mesto\n\nKyowa Hakko Kirin\n\nLaboratorium ofichem bv\n\nLannett Company Inc.\n\nLaurus Labs\n\nLebsa\n\nLonza group\n\nLusochimica S.p.A\n\nLOTUS Pharmaceutical Co., Ltd.\n\nLesaffre (Gnosis S.p.A.)\n\nMagle Chemoswed AB\n\nMallinckrodt Pharmaceuticals\n\nMedichem S.A\n\nMegafine Pharma Ltd\n\nMehta API\n\nMerck KGaA\n\nMetrochem API\n\nMicro Labs LTD\n\nMinakem High Potent S.A.\n\nMoehs Iberica SL\n\nMolcan\n\nMorepen\n\nMSN Organics Pvt, Ltd.\n\nNatco Pharma\n\nNeuland laboratories Ltd.\n\nNovartis International AG\n\nNovo Holdings A/S\n\nOlainfarm JSC\n\nOLON S.P.A.\n\nOrchid Chemicals & Pharmaceuticals Ltd\n\nOrion (Fermion)\n\nOptimus Drugs Private LTD.\n\nParatek Pharmaceuticals, Inc.\n\nPerrigo Company plc,\n\nPfizer Inc.\n\nPhyton Biotech LLC\n\nPierre Fabre\n\nPolpharma\n\nPrajna Generics Pvt. Ltd.\n\nProtex International (ICROM S.p.A.)\n\nRablon Healthcare Pvt Ltd\n\nSaneca Pharmaceuticals a.s.\n\nSanofi S.A.\n\nSolara Active Pharma\n\nSeikagaku Corporation\n\nSEQUENS (Wavelength Pharmaceuticals)\n\nShiono Chemical Co., Ltd.\n\nSM BIOMED SDN. BHD\n\nSiegfried Holding AG\n\nStandard Chemical & Pharmaceutical Co.\n\nSumitomo Dainippon Pharma Co., Ltd.\n\nSun Pharmaceutical Industries Ltd\n\nSyn-tech chem. And Pharma.Co., Ltd\n\nTakeda Pharmaceutical Company Limited\n\nTemad Co.\n\nTeva Pharmaceutical industries Ltd.\n\nUmicore\n\nUnichem Laboratories LTD.\n\nUnion Quimico Farmaceutica, S.A. UQUIFA,\n\nVenus Remedies Limited\n\nVertex Pharmaceuticals Inc.\n\nFor more information about this report visit https://www.researchandmarkets.com/r/twt43d\n\nAbout ResearchAndMarkets.com\n\nResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n\nCONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900"
    }
}